A Pilot Study to evaLuate the Role of High-dose rAnbizumab (2.0mg) in the Management of AMD in Patients With perSistent/recurrenT Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Vitreous -Retina- Macula Consultants of New York.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Vitreous -Retina- Macula Consultants of New York
Collaborator:
Genentech
Information provided by:
Vitreous -Retina- Macula Consultants of New York
ClinicalTrials.gov Identifier:
NCT01115556
First received: April 30, 2010
Last updated: December 14, 2011
Last verified: May 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |